Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
8.04
-0.02 (-0.25%)
At close: Nov 21, 2024, 4:00 PM
8.05
+0.01 (0.14%)
After-hours: Nov 21, 2024, 4:06 PM EST

Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of $1.29 billion. The enterprise value is $643.79 million.

Market Cap 1.29B
Enterprise Value 643.79M

Important Dates

The last earnings date was Tuesday, November 12, 2024, before market open.

Earnings Date Nov 12, 2024
Ex-Dividend Date n/a

Share Statistics

Novavax has 160.18 million shares outstanding. The number of shares has increased by 59.45% in one year.

Current Share Class 160.18M
Shares Outstanding 160.18M
Shares Change (YoY) +59.45%
Shares Change (QoQ) -3.50%
Owned by Insiders (%) 0.30%
Owned by Institutions (%) 53.13%
Float 143.39M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 1.30
Forward PS 2.91
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 0.73
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 0.93

Current Ratio 0.93
Quick Ratio 0.89
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -17.46

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -10.76%
Return on Capital (ROIC) n/a
Revenue Per Employee $573,683
Profits Per Employee -$184,613
Employee Count 1,543
Asset Turnover 0.53
Inventory Turnover 19.68

Taxes

In the past 12 months, Novavax has paid $5.12 million in taxes.

Income Tax 5.12M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +42.37% in the last 52 weeks. The beta is 2.09, so Novavax's price volatility has been higher than the market average.

Beta (5Y) 2.09
52-Week Price Change +42.37%
50-Day Moving Average 10.91
200-Day Moving Average 10.11
Relative Strength Index (RSI) 36.54
Average Volume (20 Days) 5,793,053

Short Selling Information

The latest short interest is 39.98 million, so 24.96% of the outstanding shares have been sold short.

Short Interest 39.98M
Short Previous Month 35.72M
Short % of Shares Out 24.96%
Short % of Float 27.88%
Short Ratio (days to cover) 5.90

Income Statement

In the last 12 months, Novavax had revenue of $885.19 million and -$284.86 million in losses. Loss per share was -$1.99.

Revenue 885.19M
Gross Profit 115.46M
Operating Income -290.02M
Pretax Income -288.88M
Net Income -284.86M
EBITDA -243.25M
EBIT -290.02M
Loss Per Share -$1.99
Full Income Statement

Balance Sheet

The company has $909.53 million in cash and $262.23 million in debt, giving a net cash position of $647.31 million or $4.04 per share.

Cash & Cash Equivalents 909.53M
Total Debt 262.23M
Net Cash 647.31M
Net Cash Per Share $4.04
Equity (Book Value) -526.44M
Book Value Per Share -3.29
Working Capital -77.32M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$90.88 million and capital expenditures -$19.96 million, giving a free cash flow of -$110.85 million.

Operating Cash Flow -90.88M
Capital Expenditures -19.96M
Free Cash Flow -110.85M
FCF Per Share -$0.69
Full Cash Flow Statement

Margins

Gross margin is 13.04%, with operating and profit margins of -32.76% and -32.18%.

Gross Margin 13.04%
Operating Margin -32.76%
Pretax Margin -31.60%
Profit Margin -32.18%
EBITDA Margin -27.48%
EBIT Margin -32.76%
FCF Margin -2.39%

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -59.45%
Shareholder Yield -59.45%
Earnings Yield -22.06%
FCF Yield -8.59%

Analyst Forecast

The average price target for Novavax is $17.83, which is 121.77% higher than the current price. The consensus rating is "Buy".

Price Target $17.83
Price Target Difference 121.77%
Analyst Consensus Buy
Analyst Count 6
Revenue Growth Forecast (5Y) -2.34%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on May 10, 2019. It was a reverse split with a ratio of 0.05:1.

Last Split Date May 10, 2019
Split Type Reverse
Split Ratio 0.05:1

Scores

Novavax has an Altman Z-Score of -3.81 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -3.81
Piotroski F-Score 3